سعر اليرجيكازون 125/50مكجم بخاخ للانف 140 جرعة 2024

Nasal spray combining the antihistamine azelastine (125 mcg) and the corticosteroid fluticasone propionate (50 mcg) per actuation, 140 actuations, marketed in Egypt by Al Esraa Pharmaceutical Optima for allergic rhinitis symptoms.

• Relief of symptoms of seasonal allergic rhinitisPopulation: Patients 6 years and olderDailyMed (U.S. National Library of Medicine)
• Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis when monotherapy with an intranasal antihistamine or glucocorticoid is not considered sufficientPopulation: Adults and adolescents 12 years and olderelectronic medicines compendium (eMC)

• Most common adverse reactions (≥2% incidence): dysgeusia, epistaxis and headache.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to azelastine hydrochloride, fluticasone propionate or any other ingredient (reactions have included anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to the active substances or to any of the excipients.International label, same formulation · electronic medicines compendium (eMC)

• Somnolence may occur; avoid engaging in hazardous activities requiring mental alertness and avoid concurrent alcohol or other CNS depressants.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Local nasal effects: epistaxis, nasal ulceration, nasal septal perforation, impaired wound healing and Candida albicans infection; periodically examine patients on long-term use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Glaucoma and cataracts may occur with nasal corticosteroids; consider ophthalmological referral in patients with vision changes or history of raised intraocular pressure, glaucoma or cataracts.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Alcohol and other CNS depressantsConcurrent use may cause additional reductions in alertness and CNS impairment; avoid.DailyMed (U.S. National Library of Medicine)
• Ritonavir (strong CYP3A4 inhibitor)Co-administration is not recommended: may markedly increase systemic fluticasone exposure, leading to Cushing syndrome and adrenal suppression.DailyMed (U.S. National Library of Medicine)
• Ketoconazole and other strong CYP3A4 inhibitorsUse with caution; may increase fluticasone exposure.DailyMed (U.S. National Library of Medicine)

• Limited data from postmarketing experience over decades of use with azelastine and fluticasone propionate in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same formulation · electronic medicines compendium (eMC)
• No data on the presence of azelastine or fluticasone propionate in human milk or effects on the breastfed infant or milk production; consider the benefits of breastfeeding and the mother's clinical need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Azelastine: Histamine H1-receptor antagonist; its major metabolite desmethylazelastine is also H1-antagonist active.
• Fluticasone propionate: Synthetic corticosteroid with potent glucocorticoid-receptor anti-inflammatory activity; the precise mechanism in allergic rhinitis is not known.